| Active Not Recruiting | Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloi NCT04258943 | Children's Oncology Group | Phase 1 / Phase 2 |
| Completed | CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey NCT03647215 | Incyte Biosciences UK | — |
| Terminated | Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML NCT01849276 | Northwestern University | Phase 1 |
| Withdrawn | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Maligna NCT01652014 | University of Medicine and Dentistry of New Jersey | Phase 2 |
| Completed | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01839916 | University of Chicago | Phase 2 |
| Withdrawn | Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Posit NCT01670084 | Mayo Clinic | Phase 2 |
| Withdrawn | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant NCT01558778 | Roswell Park Cancer Institute | N/A |
| Terminated | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies NCT01564277 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Trans NCT01427881 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia NCT01231919 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562 | City of Hope Medical Center | — |
| Completed | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Tran NCT01233921 | Martin, Paul | N/A |
| Terminated | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload NCT01159067 | City of Hope Medical Center | Phase 2 |
| Terminated | Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory NCT01159301 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Bloo NCT01076270 | Fred Hutchinson Cancer Center | N/A |
| Completed | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494 | Wake Forest University Health Sciences | N/A |
| Terminated | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer NCT01044745 | University of Nebraska | Phase 2 |
| Terminated | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating NCT00933985 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Pa NCT00860574 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML NCT00702403 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant NCT00795769 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors NCT00799461 | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Phase 3 |
| Completed | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01093586 | Case Comprehensive Cancer Center | Phase 2 |
| Terminated | Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treat NCT00540995 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Completed | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem NCT00489203 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplast NCT00459212 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Sunitinib in Treating Patients With Idiopathic Myelofibrosis NCT00387426 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, NCT00381550 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem NCT00408681 | Fred Hutchinson Cancer Center | N/A |
| Completed | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or M NCT00357305 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Tr NCT00309907 | Children's Oncology Group | Phase 2 |
| Completed | Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrom NCT00331513 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Posi NCT00316953 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgki NCT00275080 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myeloge NCT00278330 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Ph NCT00301769 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic NCT00301938 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia NCT00101088 | National Cancer Institute (NCI) | Phase 1 |
| Completed | SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic NCT00098826 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lym NCT00098423 | National Cancer Institute (NCI) | Phase 1 |
| Completed | XK469R in Treating Patients With Refractory Hematologic Cancer NCT00095797 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leuk NCT00101231 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Tran NCT01056614 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic S NCT00087204 | National Cancer Institute (NCI) | Phase 1 |
| Completed | CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, NCT00084916 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies NCT00077181 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia NCT00077467 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia NCT00054431 | National Cancer Institute (NCI) | Phase 2 |
| Completed | FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia NCT00053963 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Le NCT00052598 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction NCT00025415 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia NCT00023920 | National Cancer Institute (NCI) | Phase 2 |
| Completed | STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia NCT00015834 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer NCT00012376 | National Cancer Institute (NCI) | Phase 1 |
| Completed | BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia NCT00006213 | National Cancer Institute (NCI) | Phase 1 |
| Completed | PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, NCT00005064 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593 | Fred Hutchinson Cancer Center | N/A |